Jonathan Miller
Stock Analyst at Evercore ISI
(2.56)
# 2,968
Out of 4,993 analysts
57
Total ratings
58.5%
Success rate
2.2%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Jonathan Miller
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| PMVP PMV Pharmaceuticals | Reiterated: Buy | $4 | $1.48 | +171.19% | 3 | Sep 1, 2026 | |
| CRSP CRISPR Therapeutics AG | Reiterated: Buy | $76 | $58.33 | +30.29% | 3 | Aug 31, 2026 | |
| ARVN Arvinas | Rated: Buy | $19 → $14 | $8.30 | +68.67% | 4 | Aug 10, 2026 | |
| NTLA Intellia Therapeutics | Upgraded: Buy | $16 → $24 | $12.22 | +96.40% | 6 | Aug 7, 2026 | |
| FDMT 4D Molecular Therapeutics | Reiterated: Buy | $23 | $15.24 | +50.92% | 5 | Jul 20, 2026 | |
| EDIT Editas Medicine | Reiterated: Buy | $15 | $2.83 | +430.04% | 3 | May 27, 2026 | |
| NKTX Nkarta | Reiterated: Buy | $9 | $2.88 | +212.50% | 1 | May 18, 2026 | |
| JANX Janux Therapeutics | Reiterated: Buy | $23 → $22 | $17.01 | +29.34% | 5 | May 11, 2026 | |
| TRDA Entrada Therapeutics | Reiterated: Buy | $25 | $6.64 | +276.51% | 2 | May 5, 2026 | |
| ERAS Erasca | Reiterated: Buy | $11 → $24 | $15.04 | +59.57% | 2 | Apr 28, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $13 → $15 | $6.36 | +135.85% | 3 | Apr 13, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $1 → $13 | $1.30 | +900.00% | 2 | Mar 9, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $33 → $48 | $26.81 | +79.04% | 3 | Mar 9, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | n/a | $25.95 | - | 1 | Mar 2, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | n/a | $3.06 | - | 2 | Jan 26, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $6 | $5.43 | +10.50% | 1 | Nov 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $12 | $12.11 | -0.91% | 3 | Sep 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | n/a | $6.11 | n/a | 2 | Oct 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | n/a | $4.12 | n/a | 3 | Sep 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | n/a | $1.78 | n/a | 1 | Sep 2, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | n/a | $9.38 | n/a | 2 | May 5, 2021 |
PMV Pharmaceuticals
Sep 1, 2026
Reiterated: Buy
Price Target: $4
Current: $1.48
Upside: +171.19%
CRISPR Therapeutics AG
Aug 31, 2026
Reiterated: Buy
Price Target: $76
Current: $58.33
Upside: +30.29%
Arvinas
Aug 10, 2026
Rated: Buy
Price Target: $19 → $14
Current: $8.30
Upside: +68.67%
Intellia Therapeutics
Aug 7, 2026
Upgraded: Buy
Price Target: $16 → $24
Current: $12.22
Upside: +96.40%
4D Molecular Therapeutics
Jul 20, 2026
Reiterated: Buy
Price Target: $23
Current: $15.24
Upside: +50.92%
Editas Medicine
May 27, 2026
Reiterated: Buy
Price Target: $15
Current: $2.83
Upside: +430.04%
Nkarta
May 18, 2026
Reiterated: Buy
Price Target: $9
Current: $2.88
Upside: +212.50%
Janux Therapeutics
May 11, 2026
Reiterated: Buy
Price Target: $23 → $22
Current: $17.01
Upside: +29.34%
Entrada Therapeutics
May 5, 2026
Reiterated: Buy
Price Target: $25
Current: $6.64
Upside: +276.51%
Erasca
Apr 28, 2026
Reiterated: Buy
Price Target: $11 → $24
Current: $15.04
Upside: +59.57%
Apr 13, 2026
Reiterated: Buy
Price Target: $13 → $15
Current: $6.36
Upside: +135.85%
Mar 9, 2026
Reiterated: Buy
Price Target: $1 → $13
Current: $1.30
Upside: +900.00%
Mar 9, 2026
Reiterated: Buy
Price Target: $33 → $48
Current: $26.81
Upside: +79.04%
Mar 2, 2026
Reiterated: Buy
Price Target: n/a
Current: $25.95
Upside: -
Jan 26, 2026
Reiterated: Buy
Price Target: n/a
Current: $3.06
Upside: -
Nov 28, 2025
Reiterated: Buy
Price Target: $6
Current: $5.43
Upside: +10.50%
Sep 30, 2025
Reiterated: Buy
Price Target: $12
Current: $12.11
Upside: -0.91%
Oct 2, 2024
Rated: Buy
Price Target: n/a
Current: $6.11
Upside: n/a
Sep 16, 2024
Reiterated: Buy
Price Target: n/a
Current: $4.12
Upside: n/a
Sep 2, 2022
Initiated Coverage: Buy
Price Target: n/a
Current: $1.78
Upside: n/a
May 5, 2021
Reiterated: Buy
Price Target: n/a
Current: $9.38
Upside: n/a